

Glanbia plc

Transaction in Own Shares

1 October 2025, Glanbia plc ("**Glanbia**" or "the **Company**"), the Better Nutrition Company has been informed that Tirlán Co-operative Society Limited ("**Tirlán**") has completed the sale of 17 million ordinary shares in the Company (the "**Equity Placement Shares**"), representing approximately 6.8 percent of the Company's existing issued ordinary share capital, for a total consideration of approximately €230 million.

The price per Share in the Equity Placement was €13.55 and was determined by a bookbuild offering to institutional investors with settlement expected to occur on or around 3 October 2025.

Pursuant to the Company's existing shareholder authority to repurchase shares, the Company has participated in the Equity Placement via Glanbia's broker Davy and today purchased 7,380,073 Equity Placement Shares (representing around 2.9 percent of the Company's existing issued ordinary share capital), at a price of €13.55 per Share (the "**Buyback**"). The Equity Placement Shares purchased in the Buyback will be cancelled. Following settlement of the above transaction and subsequent share cancellation, Glanbia will have 243,793,804 ordinary shares in issue. Following the Equity Placement, Tirlán remains the largest equity investor in Glanbia plc with a holding of 43,549,029 ordinary shares.

In February 2025, the Company announced that the Board had approved a €100 million buyback authorisation. On 22 September Glanbia completed a €50 million share buyback programme under this authority. On 30 September 2025 the Board approved increasing this buyback authorisation by €50 million to fulfil Glanbia's participation in the Equity Placement. The Buyback completed today by the Company, together with the share repurchase programme which completed on 22 September 2025, fully utilises such Board authorisations.

ENDS

For further information please contact:

Glanbia plc

+353 56 777 2200

Mark Garvey, Chief Financial Officer

Liam Hennigan, Group Secretary & Head of Investor Relations:

+353 86 046 8375

Martha Kavanagh, Director of Corporate Affairs:

+353 87 646 2006

Davy

Ivan Murphy

+353 1 679 7788

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSDBGDCDDXDGUG